血清EGR1 sVE-cadherin水平与子痫前期患者病情和妊娠结局的相关性研究

doi:10.3969/j.issn.1006-6233.2025.10.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1351 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨血清早期生长反应因子1(EGR1)、可溶性血管内皮钙粘蛋白(sVE-cadherin)水平与子痫前期患者病情和妊娠结局的相关性。方法: 选取2022年1月至2024年12月我院收治的PE患者120例(PE组),根据病情分为重度PE组(65例)和轻度PE组(55例),根据妊娠结局分为不良组和良好组,另按照1∶1比例选取健康孕妇120名(对照组)。采用酶联免疫吸附法检测血清EGR1、sVE-cadherin水平。通过多因素非条件Logistic回归分析血清EGR1、sVE-cadherin水平与PE患者妊娠结局的关系;ROC曲线分析血清EGR1、sVE-cadherin水平对PE患者不良妊娠结局的预测价值。结果: 与对照组比较,PE组血清EGR1水平降低,sVE-cadherin水平升高(P<0.05)。与轻度PE组比较,重度PE组血清EGR1水平降低,sVE-cadherin水平升高(P<0.05)。120例PE患者不良妊娠结局发生率为45.83%(55/120)。与良好组比较,不良组血清EGR1水平降低,sVE-cadherin水平升高(P<0.05)。sVE-cadherin为PE患者不良妊娠结局的独立危险因素,EGR1为独立保护因素(P<0.05)。血清EGR1、sVE-cadherin水平联合预测PE患者不良妊娠结局的曲线下面积为0.891,大于血清EGR1、sVE-cadherin水平单独预测的AUC0.796、0.803(P<0.05)。结论: PE患者血清EGR1水平降低,sVE-cadherin水平升高,与PE病情加重和不良妊娠结局有关,血清EGR1、sVE-cadherin水平联合对PE患者妊娠结局有较高的预测价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：子痫前期, 早期生长反应因子1, 可溶性血管内皮钙粘蛋白

Abstract：Objective: To investigate the correlation between serum early growth response factor 1 (EGR1) and soluble vascular endothelial cadherin (sVE-cadherin) levels and the severity of disease and pregnancy outcomes in preeclampsia (PE) patients. Methods: A total of 120 PE patients treated at our hospital from January 2022 to December 2024 were selected and categorized into a severe PE group (65 cases) and a mild PE group (55 cases) based on disease severity. Based on pregnancy outcomes, patients were divided into adverse outcome and favorable outcome groups. Additionally, 120 healthy pregnant women (control group) were selected in a 1:1 ratio. Serum EGR1 and sVE-cadherin levels were measured using enzyme-linked immunosorbent assay. The relationship between serum EGR1 and sVE-cadherin levels and pregnancy outcomes in PE patients was analyzed using multivariate unconditional logistic regression. The predictive value of serum EGR1 and sVE-cadherin levels for adverse pregnancy outcomes in PE patients was assessed using ROC curve analysis. Results: Compared to the control group, the PE group exhibited decreased serum EGR1 levels and increased sVE-cadherin levels (P<0.05). Compared to the mild PE group, the severe PE group showed lower serum EGR1 levels and higher sVE-cadherin levels (P<0.05). The incidence of adverse pregnancy outcomes in the 120 PE patients was 45.83% (55/120). Compared to the favorable outcome group, the adverse outcome group had decreased serum EGR1 levels and increased sVE-cadherin levels (P<0.05). Severe PE and elevated sVE-cadherin levels were identified as independent risk factors for adverse pregnancy outcomes in PE patients, while EGR1 was an independent protective factor (P<0.05). The combined prediction of serum EGR1 and sVE-cadherin levels for adverse pregnancy outcomes in PE patients had an area under the ROC curve (AUC) of 0.891, which was greater than the AUCs for EGR1 (0.796) or sVE-cadherin (0.803) alone (P<0.05). Conclusion: In PE patients, serum EGR1 levels decrease while sVE-cadherin levels increase, which are associated with disease progression and adverse pregnancy outcomes. The combined measurement of serum EGR1 and sVE-cadherin levels has high predictive value for pregnancy outcomes in PE patients.

Key words： Preeclampsia Early growth response factor 1 Soluble vascular endothelial cadherin

引用本文:

李瑞华, 孟海云, 鹿莎, 张雯莹, 陈雪蓉. 血清EGR1 sVE-cadherin水平与子痫前期患者病情和妊娠结局的相关性研究[J]. 河北医学, 2025, 31(10): 1696-1702.
LI Ruihua, MENG Haiyun, LU Sha, et al. Study on the Correlation between Serum EGR1 sVE-Cadherin Levels Disease Severity and Pregnancy Outcomes in Preeclampsia Patients. HeBei Med, 2025, 31(10): 1696-1702.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.10.019 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I10/1696

[1] 吴晓惠,干晓琴,程薇,等.子痫前期的药物预防研究进展[J].现代妇产科进展,2024,33(5):397-400.
[2] 生殖健康及重大出生缺陷防控研究,高龄产妇妊娠期并发症防治策略研究项目组.子痫前期防治的集束化管理建议[J].中国实用妇科与产科杂志,2022,38(5):534-537.
[3] Torres-Torres J,Espino-Y-Sosa S,Martinez-Portilla R,et al.A narrative review on the pathophysiology of preeclampsia[J].Int Mol Sci,2024,25(14):7569.
[4] Heidari Z,Naeimzadeh Y,Fallahi J,et al.The role of tissue factor in signaling pathways of pathological conditions and angiogenesis[J].Curr Mol Med,2024,24(9):1135-1151.
[5] Ping Z,Feng Y,Lu Y,et al.Integrated analysis of microRNA and mRNA expression profiles in preeclampsia[J].BMC Med Genomics,2023,16(1):309.
[6] Singh A,Bhatt K S,Nguyen H C,et al.Endothelial-to-mesenchymal transition in cardiovascular pathophysiology[J].Int Mol Sci,2024,25(11):6180.
[7] Brown N,Khan F,Alshaikh B,et al.CD-34⁺ and VE-cadherin⁺ endothelial progenitor cells in preeclampsia and normotensive pregnancies[J].Pregnancy Hypertens,2019(16):42-47.
[8] 中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期高血压疾病诊治指南(2020)[J].中华妇产科杂志,2020,55(4):227-238.
[9] Hua R,Mo Y,Lin X,et al.EGR1 modulates EPHB4-induced trophoblast dysfunction in recurrent spontaneous abortion[J].Biol Reprod,2024,110(3):476-489.
[10] Mi C,Chen W,Zhang Y,et al.BaP/BPDE suppresses human trophoblast cell migration/invasion and induces unexplained miscarriage by up-regulating a novel lnc-HZ11 in extracellular vesicles: an intercellular study[J].Environ Int,2024,6(188):108750.
[11] Chen J,Zhan Y,Xu J,et al.EGR1 overexpression inhibits the occurrence of preeclampsia by binding to microRNA-574 promoter and upregulating GAB1[J].Reprod Sci,2021,28(4):1112-1121.
[12] Zhao S,Zhou J,Chen R,et al.Decreased FGF23 inhibits placental angiogenesis via the ERK1/2-EGR-1 signaling pathway in preeclampsia[J].Cytokine,2024,4(176):156508.
[13] Yu W K,Mcneil J B,Wickersham N E,et al.Angiopoietin-2 outperforms other endothelial biomarkers associated with severe acute kidney injury in patients with severe sepsis and respiratory failure[J].Crit Care,2021,25(1):48.
[14] Tseng E,Yee Teoh S S,Wang Y,et al.Elevated protease HtrA4 in the maternal circulation of preeclampsia may contribute to endothelial barrier disruption by cleaving key junctional protein VE-cadherin[J].Placenta,2019,1(76):51-53.
[15] Acikgz A S,Gk K,Tten A,et al.Evaluation of serum levels of soluble vascular endothelial (sVE)-Cadherin in early- and late-onset preeclampsia serum sVE-Cadherin levels in preeclampsia[J].Matern Fetal Neonatal Med,2024,37(1):2326304.